Sunitinib malate Gastrointestinal stromal tumour PBS authority application form (PB096)

You must lodge this form for a patient starting initial PBS subsidised treatment with sunitinib malate for metastatic or unresectable malignant gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance.


Page last updated: 13 July 2016

This information was printed Tuesday 27 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.